Patent ID: 7824851
Filing Date: 2010-11-02
Classification: A61K,A61P,C07H,C07K,C12N,C12Q,G01N

Abstract:
1. A method for treating a hepatitis C virus infection in a host, comprising (a) administering an effective amount of a 2′-branched nucleoside of the formula: or a pharmaceutically acceptable prodrug or salt thereof to the host, wherein R R R Base is a pyrimidine; (b) identifying viral resistance to the 2′-branched nucleoside in the host by detecting an amino acid 282 Ser to Thr mutation in the RNA polymerase region of the hepatitis C virus; and (c) administering to the host infected with the virus resistant to the 2′-branched nucleoside, an effective amount of one or more drugs that directly or indirectly induce a mutation in a hepatitis C virus at a location other than nucleotide 8443 (G to C) of the HCV genome or amino acid 282 Ser to Thr of the RNA polymerase region of HCV.